“Interestingly, the confirmed response rate in the intention to treat population was 32%, but this increases to 53% in the MET driven subset,” says Francesca Jackson-Spence, MBChB, BMedSc, MRCP. In ...

Disitamab vedotin plus toripalimab demonstrated a 63.6% pathologic complete response rate in HER2-expressing MIBC patients. The 12-month event-free survival rate was 92.5%, indicating promising ...

Perioperative durvalumab with neoadjuvant chemotherapy significantly improves EFS, OS, and metastasis-free survival in muscle-invasive bladder cancer. The durvalumab arm showed a 10% increase in ...

Avelumab plus BSC significantly prolongs OS and PFS in advanced urothelial carcinoma, regardless of diabetes mellitus status. The study included 700 patients, with a balanced distribution of diabetes ...

"I think this is the next step for testing the clinical activity of this agent," says David A. Braun, MD, PhD. In this video, David A. Braun, MD, PhD, describes background and design of the phase 2 ...

"The median progression-free survival and median overall survival continue to be almost double what we see with chemotherapy," says Gopa Iyer, MD. In this video, Gopa Iyer, MD, shares findings from an ...

“These data reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer," says Thomas Powles, MD, PhD. Additional follow-up data from the phase 3 EV-302 ...

ORR was 70% (95% CI, 55-82) in cohort 1 compared with 31% (95% CI, 19-45) in cohort 2. Durable antitumor activity continued to be seen with combination treatment with belzutifan (Welireg) plus ...

Radium-223 re-treatment in mCRPC patients shows a low incidence of hematologic and non-hematologic adverse events, including skeletal-related events. The study reported a median overall survival of 16 ...

Darolutamide plus ADT significantly improves radiological progression-free survival in mHSPC, reducing progression or death risk by 46%. The treatment effect is more pronounced in low-volume disease, ...

Nadofaragene firadenovec shows high efficacy in BCG-unresponsive NMIBC, with 79% achieving complete response at 3 months. The study reported a favorable safety profile, with no grade 4-5 adverse ...

"We see that among the patients who went on to receiving cystectomy, 84% are metastases free," says Pooja Ghatalia, MD. In this video, Pooja Ghatalia, MD, shares key findings from the study, “A phase ...